Literature DB >> 11887832

Bisphosphonates in dialysis and transplantation patients: efficacy and safety issues.

C Rodd1.   

Abstract

Bisphosphonates are an old class of compounds. They were used in the 1930s as antiscaling and anticorrosion agents in washing powders and water to prevent the deposition of calcium crystals. Those basic functions were later utilized in an attempt to prevent ectopic calcifications in humans. The early studies demonstrated that bisphosphonates had a strong affinity for bone. That property was first exploited when the compounds were used for "bone scans." Currently, the drugs are used for treatment of hypercalcemic conditions, abnormal bone remodelling, Paget disease, malignancy, and osteoporosis. Bisphosphonates have several important toxicities: acute renal failure, worsening renal function, reduced bone mineralization, and osteomalacia. For those reasons and others, this class of drugs has not yet been approved for use in children or in patients with severe renal insufficiency. The present review covers several aspects of bisphosphonates: molecular structure, routes of administration, pharmacology, mechanisms of action, toxicities, and exceptional uses in children with renal disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11887832

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  8 in total

1.  Use of oral bisphosphonates by older adults with fractures and impaired renal function.

Authors:  Cheryl A Sadowski; Tara Spencer; Nese Yuksel
Journal:  Can J Hosp Pharm       Date:  2011-01

Review 2.  Minimizing bone abnormalities in children with renal failure.

Authors:  Helena Ziólkowska
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 3.  The Role of Bone Biopsy in the Management of CKD-MBD.

Authors:  Ana Carina Ferreira; Martine Cohen-Solal; Patrick C D'Haese; Aníbal Ferreira
Journal:  Calcif Tissue Int       Date:  2021-03-26       Impact factor: 4.333

4.  Reversal of hypercalcemic acute kidney injury by treatment with intravenous bisphosphonates.

Authors:  Ari Auron; Leyat Tal; Tarak Srivastava; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2008-10-07       Impact factor: 3.714

Review 5.  The role of bisphosphonates in diseases of childhood.

Authors:  Tarak Srivastava; Uri S Alon
Journal:  Eur J Pediatr       Date:  2003-09-11       Impact factor: 3.183

Review 6.  Bone fragility in patients with chronic kidney diseases.

Authors:  Martine Cohen-Solal; Thomas Funch-Brentano; Pablo Urena
Journal:  Endocr Connect       Date:  2020-03-01       Impact factor: 3.335

Review 7.  Bone Fragility Fractures in CKD Patients.

Authors:  Ana Pimentel; Pablo Ureña-Torres; Jordi Bover; Jose Luis Fernandez-Martín; Martine Cohen-Solal
Journal:  Calcif Tissue Int       Date:  2020-11-21       Impact factor: 4.333

8.  Case report: Osteomalacia due to bisphosphonate treatment in a patient on hemodialysis.

Authors:  Masaki Hatano; Izuru Kitajima; Seizo Yamamoto; Masaki Nakamura; Kazuya Isawa; Yutaka Hirota; Junichi Hoshino; Naoki Sawa; Yoshifumi Ubara
Journal:  BMC Nephrol       Date:  2021-09-03       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.